Drug Profile
Human insulin biosimilar - Marvel Lifesciences
Alternative Names: SolumarvLatest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator Marvel LifeSciences Private Limited
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Submission Withdrawal Diabetes mellitus
Most Recent Events
- 20 Nov 2015 The Committee for Medicinal Products for Human Use (CHMP) does not recommend approval of Solumarv for Diabetes mellitus in European Union
- 01 Nov 2015 Preregistration for Diabetes mellitus in European Union (IV) before November 2015
- 05 Dec 2011 Preregistration for Diabetes mellitus in European Union (IV)